ASX - Delayed Quote AUD

4DMedical Limited (4DX.AX)

Compare
0.5100
+0.0300
+(6.25%)
As of 2:26:07 PM GMT+11. Market Open.
Loading Chart for 4DX.AX
DELL
  • Previous Close 0.4800
  • Open 0.4850
  • Bid 0.5050 x --
  • Ask 0.5100 x --
  • Day's Range 0.4850 - 0.5100
  • 52 Week Range 0.4100 - 0.8300
  • Volume 395,373
  • Avg. Volume 925,902
  • Market Cap (intraday) 211.209M
  • Beta (5Y Monthly) 1.34
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1000
  • Earnings Date Feb 26, 2025 - Mar 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.85

4DMedical Limited operates as a medical technology company in the United States and Australia. It engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. The company also offers X-ray velocimetry lung ventilation analysis software (XV LVAS), a lung airflow imaging software, that provides lung health detail from X-Ray scans; computed tomography lung ventilation analysis software (CT LVAS), an image processing software which operates on CT scans to provide functional lung health detail; XV Scanner, a lung function scanner; and Permetium, a multi-function imaging system for pulmonary investigations. The company was incorporated in 2012 and is based in Carlton, Australia.

4dmedical.com

145

Full Time Employees

June 30

Fiscal Year Ends

Recent News: 4DX.AX

View More

Performance Overview: 4DX.AX

Trailing total returns as of 2/13/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

4DX.AX
6.25%
S&P/ASX 200 [XJO]
4.83%

1-Year Return

4DX.AX
24.44%
S&P/ASX 200 [XJO]
13.32%

3-Year Return

4DX.AX
43.33%
S&P/ASX 200 [XJO]
18.07%

5-Year Return

4DX.AX
65.31%
S&P/ASX 200 [XJO]
19.96%

Compare To: 4DX.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4DX.AX

View More

Valuation Measures

As of 2/12/2025
  • Market Cap

    198.78M

  • Enterprise Value

    173.30M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    58.31

  • Price/Book (mrq)

    2.80

  • Enterprise Value/Revenue

    56.83

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.95%

  • Return on Equity (ttm)

    -50.54%

  • Revenue (ttm)

    3.75M

  • Net Income Avi to Common (ttm)

    -35.98M

  • Diluted EPS (ttm)

    -0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.61M

  • Total Debt/Equity (mrq)

    7.22%

  • Levered Free Cash Flow (ttm)

    -17.56M

Research Analysis: 4DX.AX

View More

People Also Watch